

Trovogene, Inc.
Form DEFA14A
December 09, 2015

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant X

Filed by a Party other than the Registrant O

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

Trovogene, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:

Edgar Filing: Trovogene, Inc. - Form DEFA14A

- (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:
-

Trovogene Adjourns Special Meeting of Stockholders to December 23, 2015

SAN DIEGO, CA December 9, 2015 Trovogene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that its Special Meeting of Stockholders scheduled for, and convened on December 9, 2015, was adjourned due to the lack of requisite quorum. The meeting has been adjourned to December 23, 2015 at 9:00 a.m. PST at 11120 Roselle Street, San Diego, California 92121.

During the period of the adjournment, stockholders holding shares as of the record date of October 12, 2015, are entitled to and are being requested to vote.

The Company encourages all stockholders who have not yet voted to do so before December 22, 2015 at 11.59 p.m. EST. Stockholders of record may vote online at www.pstvote.com/trovagenespecial2015 or by mail by sending their completed proxies to Philadelphia Stock Transfer, Inc., 2320 Haverford Rd., Suite 230, Ardmore, PA 19003. Proxies previously submitted in respect of the meeting will be voted on at the adjourned meeting unless properly revoked.

No changes have been made to the proposal to be voted on by stockholders at the special meeting. The Company's proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC's website at www.sec.gov.

About Trovogene, Inc.

Headquartered in San Diego, California, Trovogene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovogene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Contact

Investor Relations

David Moskowitz and Amy Caterina
Investor Relations

Media Relations

Ian Stone
Account Director

Edgar Filing: Trovogene, Inc. - Form DEFA14A

Trovogene, Inc.
858-952-7593
ir@trovogene.com

Canale Communications, Inc.
619-849-5388
ian@canalecomm.com

###

Trovogene Inc. | 11055 Flintkote Avenue | San Diego | CA 92121 | Tel.: USA [+1] 888-391-7992
